After-Hours Stock Movers 07/19: (AMRX) (CCK) (IBM) Higher; (ARDX) (RCUS) (PPG) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro improve AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
Ardelyx's (ARDX) Shares Plunge as Tenapanor's Deficiencies Identified by FDA 'Take Approval Off the Table'
July 20, 2021 9:57 AM EDTOn July 19th, 2021, Ardelyx, Inc (NASDAQ: ARDX) disclosed a letter from the US Food and Drug Administration (FDA) relating to its New Drug application for Tenapanor the companys drug candidate for the control of serum phosphorus in adult patients with chronic kidney disease (CKD).
The agency notified the company of identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time, as well as denied a follow-up meeting request by ARDX.
The FDA move took the market by surprise, sending the companys... More



